Overall verdict
Buy
6.7/10
1-year performance
+28.02%
Score breakdown
Up 28.0% over 1 year, 75% of the 52-week range.
Strongest: Profitability 9.2/10. Weakest: Growth 1.8/10.
28 analysts, target +0.0% vs the price.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications ; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors ; Orencia for active rheumatoid arthritis and psoriatic arthritis ;
Yervoy for the treatment of unresectable or metastatic melanoma ; Reblozyl to treat anemia ; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma ; Opdualag to treat unresectable or metastatic melanoma ; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis ; Abecma for the treatment of patients with relapsed or refractory multiple myeloma ;
Sotyktu to treat moderate-to-severe plaque psoriasis ; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) ; and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE ; Revlimid, an oral immunomodulatory drug for multiple myeloma ; Pomalyst/Imnovid for multiple myeloma ;
Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia ; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Sector
Health Care
Industry
Pharmaceuticals
Primary listing
Nyse
United States
CEO
Christopher Boerner
Founded
1887
Employees
32 500
Revenue / employee
1.5M USD
Next earnings
February 4, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.48%
- FMR LLC1.39%
- Bank of New York Mellon Corp0.97%
- Rest of the register95.17%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
68.64 USD
52-week low
45.27 USD
1-year performance
28.02%
Rising
Year-to-date performance
17.89%
Rising
Drawdown
-8.61%
Mild pullback
Position in the 52-week range
75% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned less, while shaking 1.7 times harder.
$10,000 placed at the end of December 2000 are worth today
| Bristol-Myers Squibb | $23,859 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 1.7 times as much as the world ETF.
- Worst fall:-68 % between December 2000 and March 2003. $10,000 placed at the top fell to $3,207. The world ETF, at worst: -53 %. Back to its high in 122 months.
Bristol-Myers Squibb earned less than the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Bristol-Myers Squibb: $23,859
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 45.03 USD - 59.62 USD (2 methods agree)
The price implies growth of 0.13% per year; the company grows at 2.54%.
Gross margin 66.3%, net margin 18.5%, ROIC 14.0%, ROE 44.1%.
Net margin
18.47%
Exceptional
Sector 9.96%|S&P 13.40%
Gross margin
66.32%
High
Return on equity (ROE)
44.06%
Exceptional
Sector 6.73%|S&P 17.06%
Return on invested capital (ROIC)
14.02%
Exceptional
Free cash flow margin (FCF)
18.55%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.00x
High
Margin stability
14.9 pts
Very uneven
Revenue to net income
Growth
1.8/10Revenue up 7.0% over 1 year, 2.5% a year over 5.
Revenue (trailing 12 months)
50.0Md USD
Revenue growth (1y)
6.99%
Solid
Revenue growth (3y)
4.41%
Moderate
EPS growth (1y)
-2.44%
Declining
EPS CAGR (5y)
—
EPS revisions (3 months)
-7.29%
Sharply revised down
Valuation
8.7/10P/E 13.9x, forward P/E 11.9x, EV/EBITDA 8.3x, PEG 0.27. The multiple sits in the 50th percentile of its own 5-year history.
P/E (TTM)
13.9x
Cheap
Sector 27.8x|S&P 23.6x
Forward P/E
11.9x
Fair
EV / EBITDA
8.3x
Cheap
Sector 14.3x|S&P 15.5x
PEG
0.27
Growth unpriced
Sector 0.88|S&P 0.91
Fair value (reverse DCF)
51.16 USD
Overvalued
P/E vs its own 5-year history
among the 50% lowest valuations
In line with its history
Market cap
128Md USD
Financial strength
6.2/10Cash covers 28.1% of the debt, net debt/EBITDA 1.9x.
Net debt / EBITDA
1.9x
Tight
Gearing (net debt / equity)
137.71%
Stretched
Cash
12.6Md USD
Cash / market cap
9.81%
Solid
Cash / total debt
28.08%
Tight
Interest coverage
10.0x
Solid
Net debt
32.2Md USD
Equity
23.4Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 62.80 USD
- MM2061.62
- MM5062.18
- MM20060.22
- RSI 1453.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.13%
200-day average slope, 3 months
+6.79%
50-day average slope, 1 month
-2.79%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.23 % per day
Volatility change
+29.00%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 5.26 (8) | 6.44 (27) | 50 234 (24) | 17 923 (8) | 10 743 (9) |
| 2027 | 5.86 (10) | 6.70 (28) | 48 801 (26) | 19 254 (9) | 11 508 (9) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 10, 2026.
Same sub-industry: 503 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AZN | 7.1 | 7.0 | 286Md USD | 26.7x | 17.7 % | 7.1 % | 14.4 % | 1.2x | 3.6 % | 3.7 % | ||
| 2 | BMY | 6.7 | 6.9 | 128Md USD | 13.9x | 18.5 % | 7.0 % | 14.0 % | 1.9x | 7.2 % | 28.0 % | ||
| 3 | NOVO B | 6.2 | 7.7 | 178Md USD | 10.7x | 33.9 % | 5.6 % | 38.1 % | 0.7x | 6.0 % | -8.5 % | ||
| 4 | ROP | 6.2 | 6.4 | 385Md USD | 26.2x | 20.3 % | 1.7 % | 21.8 % | 0.8x | 4.7 % | 42.5 % | ||
| 5 | NOVN | 6.1 | 6.5 | 295Md USD | 32.0x | 18.0 % | 6.0 % | 13.5 % | 1.0x | 5.0 % | 29.2 % | ||
| 6 | LLY | 6.0 | 5.1 | 1.4T USD | 47.2x | 31.9 % | 38.6 % | 36.3 % | 1.2x | 1.5 % | 48.7 % | ||
| 7 | JNJ | 5.6 | 5.2 | 675Md USD | 42.5x | 16.2 % | 5.9 % | 13.6 % | 0.9x | 3.1 % | 48.1 % | ||
| 8 | MRK | 5.4 | 3.6 | 363Md USD | 150.3x | 3.6 % | 5.5 % | 2.6 % | 1.2x | 4.1 % | 68.5 % | ||
| 9 | PFE | 5.2 | 4.6 | 168Md USD | 42.1x | 6.3 % | -0.4 % | 2.7 % | 2.3x | 7.0 % | 20.3 % |
